Overview

Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Bivatuzumab mertansine
Maytansine